Agenus INC 8-K filings

Agenus has entered into a royalty financing agreement with Ligand Pharmaceuticals, securing an initial $75 million to support the development of its cancer therapies, with potential for up to $200 million in total.

Agenus Inc. will implement a 1-for-20 reverse stock split effective April 12, 2024, after receiving shareholder approval at a special meeting.

Agenus announced promising clinical trial results for its BOT/BAL combination therapy across multiple cancer types, along with its fourth quarter and full year 2023 financial results.

Agenus Inc. is proposing a 1-for-20 reverse stock split to increase its share price, maintain Nasdaq listing compliance, and attract a broader range of investors.

Agenus Inc. has received a $25 million milestone payment from Bristol Myers Squibb following the achievement of a development milestone in their licensing agreement.